Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 95 of 1821 for:    "bone marrow" | Recruiting, Not yet recruiting Studies

Prospective Evaluation of PRP and BMC Treatment to Accelerate Healing After ACL Reconstruction

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04205656
Recruitment Status : Recruiting
First Posted : December 19, 2019
Last Update Posted : January 27, 2020
Sponsor:
Collaborators:
United States Department of Defense
Office of Naval Research (ONR)
Information provided by (Responsible Party):
Steadman Philippon Research Institute

Tracking Information
First Submitted Date  ICMJE December 4, 2019
First Posted Date  ICMJE December 19, 2019
Last Update Posted Date January 27, 2020
Actual Study Start Date  ICMJE January 2, 2020
Estimated Primary Completion Date December 1, 2022   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: December 17, 2019)
Incidence of Treatment-Emergent Adverse Events [ Time Frame: 18 months ]
Occurrence of adverse events
Original Primary Outcome Measures  ICMJE Same as current
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: December 17, 2019)
  • Patient reported outcome questionnaire [ Time Frame: screening, baseline, two weeks post-surgery, then every week for 8 weeks post-surgery; 3, 6 12 and 18 months post-surgery ]
    SF-12 Short Form General Health Survey Patient Satisfaction
  • Measure signature cellular profile of BMC [ Time Frame: Day of Surgery ]
    Flow cytometer to analyze BMC cell concentrations
  • Measure plasma levels of pro-inflammatory factors in BMC [ Time Frame: Day of Surgery ]
    Multiplex analysis of pro-inflammatory cytokines and chemokines using Luminex 200®
  • Measure plasma levels of pro-inflammatory factors in LP-PRP [ Time Frame: Day of Surgery ]
    Multiplex analysis of pro-inflammatory cytokines and chemokines using Luminex 200®
  • Quantitative Magnetic Resonance Imaging (MRI) [ Time Frame: screening, baseline; 6 and 18 months post-surgery ]
    Images acquired on a 3T Siemens Magnetom Skyra-fit scanner
  • DSX: three dimensional (3D) to measure motion of the knee using dynamix x-ray software [ Time Frame: 6 and 18 months post-surgery ]
    Up to three brief X-ray exposures (5 frames at 100 frames/s, 0.05 s) will be acquired
  • Computerized tomography (CT): 3D geometry of bony anatomy using a series of x-rays [ Time Frame: 6 months post-surgery ]
    single, bilateral knee CT scan using Toshiba Aquilon Premium 160 CT scanner
  • Patient Reported Outcome questionnaire [ Time Frame: screening, baseline, two weeks post-surgery, then every week for 8 weeks post-surgery; 3, 6 12 and 18 months post-surgery ]
    IKDC - International Knee Documentation Committee Score
  • Patient Reported Outcome questionnaire [ Time Frame: screening, baseline, two weeks post-surgery, then every week for 8 weeks post-surgery; 3, 6 12 and 18 months post-surgery ]
    WOMAC - Western Ontario & McMaster Universities Osteoarthritis Index
  • Patient Reported Outcome questionnaire [ Time Frame: screening, baseline, two weeks post-surgery, then every week for 8 weeks post-surgery; 3, 6 12 and 18 months post-surgery ]
    Lysholm Score
  • Patient Reported Outcome questionnaire [ Time Frame: screening, baseline, two weeks post-surgery, then every week for 8 weeks post-surgery; 3, 6 12 and 18 months post-surgery ]
    Tegner Activity Scale
  • Patient Reported Outcome questionnaire [ Time Frame: screening, baseline, two weeks post-surgery, then every week for 8 weeks post-surgery; 3, 6 12 and 18 months post-surgery ]
    NRS (NUMERICAL RATING SCALE) for Pain
  • Motion Assessment [ Time Frame: screening, baseline; 6 months post-surgery ]
    3D video motion capture
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Prospective Evaluation of PRP and BMC Treatment to Accelerate Healing After ACL Reconstruction
Official Title  ICMJE Prospective Evaluation of Platelet-Rich Plasma and Bone Marrow Concentrate Treatment to Accelerate Healing After Anterior Cruciate Ligament Reconstruction
Brief Summary This is a prospective, randomized, placebo-controlled trial to evaluate potential beneficial effects of leukocyte-poor platelet rich plasma and bone marrow concentrate on the healing and health of critical joint tissues in the knee following anterior cruciate ligament (ACL) reconstruction. Bone marrow contains stem cells which can change into cells of various different tissue types, while platelet rich plasma contains growth factors. This trial will compare the two procedures against placebo.
Detailed Description

This is a prospective, randomized, placebo-controlled trial. Patients will be randomized into three groups: Concentrated Bone Marrow Concentrate (BMC), Platelet-Rich Plasma (PRP) or Placebo. BMC subjects will have bone marrow aspirated from the subjects iliac crests and the cellular rich portion will be concentrated and subsequently injected into the subjects' symptomatic knee during ACL reconstruction surgery. PRP subjects will have a venous blood draw and the resulting PRP will be injected into the symptomatic knee during ACL reconstruction surgery. Follow-up visits involving imaging and biomotion testing will take place at 2 weeks, 6 months and 18 months after the ACL reconstruction surgery.

The purpose of this study is to evaluate potential beneficial effects of leukocyte-poor platelet-rich plasma (LP-PRP) and bone marrow concentrate (BMC) on the healing and health of all critical joint tissues (grafts/ligaments, meniscus and cartilage) in the knee following anterior cruciate ligament reconstruction (ACLR). Key aspects of this proposal include our well-developed methodologies to quantify and correlate cytokines, chemokines, growth factors in PRP and progenitor cells in BMC, clinical outcomes and imaging following ACLR. The overarching goal of this randomized control trial is to establish a biological signature of PRP and BMC that will be indicative for optimal recovery after ACLR. The long-term goal of our research is to better understand the efficacy of orthobiologic approaches to improve clinical outcomes, enhance graft healing and mitigate post-traumatic osteoarthritis (PTOA) in a cohort of patients that have undergone ACLR.

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Phase 2
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Masking Description:
Outcomes assessor
Primary Purpose: Treatment
Condition  ICMJE Osteoarthritis, Knee
Intervention  ICMJE
  • Biological: Leukocyte-Poor Platelet Rich Plasma (LP-PRP)
    Participants will have a knee injected with Platelet-Rich Plasma (PRP) obtained from a venous whole blood draw from the vein.
  • Biological: Bone Marrow Concentrate (BMC)
    Participants will have a knee injected with BMC stem cells harvested from the iliac crest
  • Other: Control group (Placebo)
    Participants will undergo ACLR surgery with no injection into their knee.
Study Arms  ICMJE
  • Experimental: Leukocyte-Poor Platelet Rich Plasma (LP-PRP)
    Participants will have a knee injected with Platelet-Rich Plasma (PRP) obtained from a venous whole blood draw from the vein.
    Intervention: Biological: Leukocyte-Poor Platelet Rich Plasma (LP-PRP)
  • Experimental: Bone Marrow Concentrate (BMC)
    Participants will have a knee injected with BMC stem cells harvested from the iliac crest
    Intervention: Biological: Bone Marrow Concentrate (BMC)
  • Placebo Comparator: Control
    Patients randomized in the placebo arm will undergo their standard of care treatment and will not receive LP-PRP or BMC.
    Intervention: Other: Control group (Placebo)
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: December 17, 2019)
99
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE December 1, 2022
Estimated Primary Completion Date December 1, 2022   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria: Subjects will be included if all the following criteria are met:

  1. Age 16-50 years at the time of Anterior Cruciate Ligament Reconstruction (ACLR) surgery;
  2. Acute ACL injury within 6 months of scheduled ACLR surgery;
  3. Scheduled for unilateral, primary ACLR with a BTB (bone-patellar tendon-bone) autograft;
  4. The following concomitant injuries are allowed:

    1. Meniscal injuries of all types, grades and regardless of surgical treatment;
    2. Articular chondral injury that can be addressed with debridement or chondroplasty;
    3. Tibial impaction fractures;
    4. Non-operative sprains/injuries of MCL or LCL;
  5. Willing and able to comply with all required post-operative visits, biomotion and imaging tests, the self-completion of questionnaires and other trial procedures.

Exclusion Criteria: Subjects will be excluded if any of the following criteria are met:

  1. Inability to provide informed consent;
  2. Women who are pregnant;
  3. Previous surgery for either knee except in cases of prior diagnostic arthroscopy and/or minimal debridement;
  4. Significant osteoarthritis (OA) of the knee (e.g. grade 4 with cystic changes and/or significant osteophytes);
  5. Concomitant cartilage restoration procedure in the operative knee;
  6. Biologic treatment (e.g. PRP, BMC, prolotherapy, etc.) in the operative knee within 6 months of ACLR surgery;
  7. Steroid injections in the operative knee within 3 months of ACLR surgery;
  8. Open growth plates (determined by the treating physician based on standard-of-care preoperative knee radiographs);
  9. History of deep vein thrombosis (DVT) or pulmonary embolism (PE) that requires additional anticoagulation beyond usual post-operative standard of care;
  10. Current or known history of significant active autoimmune disease (i.e. rheumatoid arthritis and SLE);
  11. Incompatible MRI hardware/devices and/or inability to safely undergo MRI per the MRI safety screening questionnaire;
  12. Known balance or vestibular disorders, if in the opinion of the Principal Investigator or delegated clinician may affect ability to safely comply with study procedures;
  13. History of significant radiation exposure, e.g. due to radiation therapy or occupational exposure;
  14. Active malignancy of any type or history of a malignancy within 2 years of informed consent (with the exception of subjects with a history of treated basal or squamous cell carcinoma);
  15. Concurrent or previous participation in another clinical trial within 30 days prior to informed consent;

    1. Concurrent enrollment in DOD Project 4, Vail Health Hospital IRB # 2018-20, is allowed while subjects on this study are in the 18-month follow-up period;
    2. Concurrent enrollment in non-interventional registry studies or blood-banking/biomarker studies is allowed;
  16. History of substance abuse (drug or alcohol) that may interfere with the subject's ability to cooperate and comply with the trial procedures;
  17. Severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with trial participation or investigational product administration or may interfere with the interpretation of trial results and, in the judgment of the Principal Investigator or delegated clinician, would make the subject inappropriate for entry into this trial.

    Subjects will be withdrawn from the study (Screen Failures) after providing informed consent and/or at the time of ACLR surgery if they meet any of the following criteria:

  18. Concurrent reconstruction of any knee ligaments other than the ACL;
  19. ACLR which requires the following concomitant treatments: bone plating, metal implants (with the exception of titanium interference screws) or microfracture;
  20. Inability to collect sufficient research samples (e.g. less than the minimum required amount of BMA is harvested, or clotting occurs).
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 16 Years to 50 Years   (Child, Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Contact: Holly del Junco 970-238-8086 hdeljunco@sprivail.org
Contact: Suzanne L Page, JD 970-401-8770 spage@sprivail.org
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT04205656
Other Study ID Numbers  ICMJE 2019-13
Has Data Monitoring Committee No
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: Undecided
Responsible Party Steadman Philippon Research Institute
Study Sponsor  ICMJE Steadman Philippon Research Institute
Collaborators  ICMJE
  • United States Department of Defense
  • Office of Naval Research (ONR)
Investigators  ICMJE
Principal Investigator: Peter Millett, MD The Steadman Clinic
PRS Account Steadman Philippon Research Institute
Verification Date January 2020

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP